Bible moralisée, texte latin avec la traduction, jusqu'à Isaïe.

Commençant par : « In principio creavit Deus... » Glose : « Creatio lucis angelorum creationem... Au commencement Dieu crea... La creation de lumiere emporte la creation des anges... » et finissant par : «... quia excidisti sepulcrum ». Glose : «... et accederent ad verum sacrificium... car tu as taillé et appareillé ton sepulcre... et venissent au vray sacrifice ».

Partie d'une « Bible historiée toute figurée ».

Miniatures italiennes à chaque page. — Cet exemplaire n'est pas, comme on l'a cru, celui qui avait appartenu à la reine Jeanne d'Évreux, femme de Charles le Bel, puis au roi Charles V.

Divers cartonnages de momie. Egyptien 164

Scarabée poussant le disque solaire ; Nout aux aîles déployées et une scène inspirée du chapitre 89 du Livre des Morts (Isis et Nephtys veille sur le défunt momifié dont s’éloigne le ba) ; représentation de génies funéraires.Une formule funéraire très endommagée.Très similaire à E 165

Report on the Iowa Ethics and Campaign Disclosure Board for the year ended June 30, 2009

Report on the Iowa Ethics and Campaign Disclosure Board for the year ended June 30, 2009

Report on recommendations to the Iowa Ethics and Campaign Disclosure Board for the year ended June 30, 2010

Audit report of the Iowa Ethics and Campaign Disclosure Board for the year ended June 30, 2010

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene.

Clozapine (CLO), an atypical antipsychotic, depends mainly on cytochrome P450 1A2 (CYP1A2) for its metabolic clearance. Four patients treated with CLO, who were smokers, were nonresponders and had low plasma levels while receiving usual doses. Their plasma levels to dose ratios of CLO (median; range, 0.34; 0.22 to 0.40 ng x day/mL x mg) were significantly lower than ratios calculated from another study with 29 patients (0.75; 0.22 to 2.83 ng x day/mL x mg; P < 0.01). These patients were confirmed as being CYP1A2 ultrarapid metabolizers by the caffeine phenotyping test (median systemic caffeine plasma clearance; range, 3.85; 3.33 to 4.17 mL/min/kg) when compared with previous studies (0.3 to 3.33 mL/min/kg). The sequencing of the entire CYP1A2 gene from genomic DNA of these patients suggests that the -164C > A mutation (CYP1A2*1F) in intron 1, which confers a high inducibility of CYP1A2 in smokers, is the most likely explanation for their ultrarapid CYP1A2 activity. A marked (2 patients) or a moderate (2 patients) improvement of the clinical state of the patients occurred after the increase of CLO blood levels above the therapeutic threshold by the increase of CLO doses to very high values (ie, up to 1400 mg/d) or by the introduction of fluvoxamine, a potent CYP1A2 inhibitor, at low dosage (50 to 100 mg/d). Due to the high frequency of smokers among patients with schizophrenia and to the high frequency of the -164C > A polymorphism, CYP1A2 genotyping could have important clinical implications for the treatment of patients with CLO.